![]() | Review waiting, please be patient.
This may take 4 months or more, since drafts are reviewed in no specific order. There are 2,675 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Submission declined on 11 May 2024 by
Theroadislong (
talk). This submission's references do not show that the subject
qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published,
reliable,
secondary sources that are
independent of the subject (see the
guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see
technical help and learn about
mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. | ![]() |
Submission declined on 11 May 2024 by
DoubleGrazing (
talk). This submission is not adequately supported by
reliable sources. Reliable sources are required so that information can be
verified. If you need help with referencing, please see
Referencing for beginners and
Citing sources. The content of this submission includes material that does not meet Wikipedia's
minimum standard for inline citations. Please
cite your sources using
footnotes. For instructions on how to do this, please see
Referencing for beginners. Thank you. Declined by
DoubleGrazing 2 months ago. | ![]() |
![]() | This article is an
autobiography or has been extensively edited by the subject or by someone connected to the subject. (May 2024) |
John F. Crary, MD-PhD | |
---|---|
![]() | |
Born | 1973 (age 50–51)
New York, New York, U.S. |
Alma mater | Brown University, SUNY Downstate Medical Center, Columbia University Medical Center |
Known for | Study of tauopathy |
Scientific career | |
Fields | Neuropathology |
Institutions | Icahn School of Medicine at Mount Sinai |
John F. Crary, MD-PhD (born 1973) is an American neuropathologist and experimental neurobiologist. He is a full professor with tenure at the Icahn School of Medicine at Mount Sinai where he founded and co-directs the Neuropathology Brain Bank & Research CoRE. [1]
John F. Crary was born in New York City and raised in Brooklyn. He attended Saint Ann's School. His father, Calvert D. Crary, was a Wall Street analyst specializing in litigation and biotechnology. [2] Crary pursued his undergraduate studies at Brown University, majoring in neuroscience.
Crary underwent his MD-PhD training at SUNY Downstate graduating in 2006 as a commencement speaker at Carnegie Hall. [3][ failed verification] His thesis work focused on PKMzeta in Alzheimer's disease under the mentorship of two leading neuroscientists: Dr. Todd Sacktor, MD, known for his discovery of PKMzeta, [4] and Suzanne Mirra, MD who devised the CERAD criteria for the neuropathological diagnosis of Alzheimer's disease. [5] He completed his anatomical and neuropathology residency and fellowship at Columbia University, where he was mentored by Michael Shelanski, MD-PhD. There, he studied "tangle-only" dementia which led to the characterization of primary age-related tauopathy (PART), [6] which received some attention at the time. [7] The proposal that PART is a unique subgroup of dementia patients distinct from Alzheimer's Disease was highly controversial, [8] and still remains a highly researched topic. [9] The original description of PART has now been cited 1323 times as of May of 2024 according to Google Scholar.
In 2014, Crary moved to the Icahn School of Medicine at Mount Sinai, establishing a new laboratory and brain bank focused on movement disorders and chronic traumatic encephalopathy. [10] Crary is a frequent invited lecturer at various institutions including the New York Academy of the Sciences, [11] the American Association of Neuropathologists, [12] and others.
Dr. Crary has led efforts to define post-mortem diagnostic criteria for various tauopathies. This includes primary age-related tauopathy, [13] aging-related tau astrogliopathy, [14] chronic traumatic encephalopathy, [15] [16] and progressive supranuclear palsy. [17] He also contributed substantially to understanding the neurological consequences of neuroinfectious diseases such as HIV [18] and SARS-CoV-2. [19]
His genetic studies of on PART [21] and PSP have received considerable attention. [22]
Crary was the first to apply artificial intelligence / machine learning techniques to the histomorphological assessment of neurodegeneration in human brain digital whole slide images of autopsy brain tissues. [23] He has pioneered the use of convolutional neural networks for analyzing whole slide images from dementia patients. Dr. Crary developed an AI/ML algorithm capable of obtaining a pre-mortem tissue diagnosis of Parkinson's disease. [24] Dr. Crary's team was the first to apply convolutional neural networks to assessing tau pathology. [25] [26] The Crary lab showed that deep learning algorithms can predict cognitive function. [27] Using multiple instance learning, Dr. Crary's team developed an approach to measuring brain aging, termed HistoAge, [28] an approach that may help advancing our understanding of age-acceleration. [29]
He is an editor of Acta Neuropathologica [30] and Free Neuropathology. [31]
{{
cite journal}}
: CS1 maint: numeric names: authors list (
link)
{{
cite journal}}
: CS1 maint: numeric names: authors list (
link)
{{
cite journal}}
: CS1 maint: numeric names: authors list (
link)
{{
cite journal}}
: CS1 maint: numeric names: authors list (
link)
{{
cite journal}}
: CS1 maint: numeric names: authors list (
link)
{{
cite journal}}
: CS1 maint: numeric names: authors list (
link)
{{
cite journal}}
: CS1 maint: numeric names: authors list (
link)
{{
cite journal}}
: CS1 maint: numeric names: authors list (
link)
![]() | Review waiting, please be patient.
This may take 4 months or more, since drafts are reviewed in no specific order. There are 2,675 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Submission declined on 11 May 2024 by
Theroadislong (
talk). This submission's references do not show that the subject
qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published,
reliable,
secondary sources that are
independent of the subject (see the
guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see
technical help and learn about
mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. | ![]() |
Submission declined on 11 May 2024 by
DoubleGrazing (
talk). This submission is not adequately supported by
reliable sources. Reliable sources are required so that information can be
verified. If you need help with referencing, please see
Referencing for beginners and
Citing sources. The content of this submission includes material that does not meet Wikipedia's
minimum standard for inline citations. Please
cite your sources using
footnotes. For instructions on how to do this, please see
Referencing for beginners. Thank you. Declined by
DoubleGrazing 2 months ago. | ![]() |
![]() | This article is an
autobiography or has been extensively edited by the subject or by someone connected to the subject. (May 2024) |
John F. Crary, MD-PhD | |
---|---|
![]() | |
Born | 1973 (age 50–51)
New York, New York, U.S. |
Alma mater | Brown University, SUNY Downstate Medical Center, Columbia University Medical Center |
Known for | Study of tauopathy |
Scientific career | |
Fields | Neuropathology |
Institutions | Icahn School of Medicine at Mount Sinai |
John F. Crary, MD-PhD (born 1973) is an American neuropathologist and experimental neurobiologist. He is a full professor with tenure at the Icahn School of Medicine at Mount Sinai where he founded and co-directs the Neuropathology Brain Bank & Research CoRE. [1]
John F. Crary was born in New York City and raised in Brooklyn. He attended Saint Ann's School. His father, Calvert D. Crary, was a Wall Street analyst specializing in litigation and biotechnology. [2] Crary pursued his undergraduate studies at Brown University, majoring in neuroscience.
Crary underwent his MD-PhD training at SUNY Downstate graduating in 2006 as a commencement speaker at Carnegie Hall. [3][ failed verification] His thesis work focused on PKMzeta in Alzheimer's disease under the mentorship of two leading neuroscientists: Dr. Todd Sacktor, MD, known for his discovery of PKMzeta, [4] and Suzanne Mirra, MD who devised the CERAD criteria for the neuropathological diagnosis of Alzheimer's disease. [5] He completed his anatomical and neuropathology residency and fellowship at Columbia University, where he was mentored by Michael Shelanski, MD-PhD. There, he studied "tangle-only" dementia which led to the characterization of primary age-related tauopathy (PART), [6] which received some attention at the time. [7] The proposal that PART is a unique subgroup of dementia patients distinct from Alzheimer's Disease was highly controversial, [8] and still remains a highly researched topic. [9] The original description of PART has now been cited 1323 times as of May of 2024 according to Google Scholar.
In 2014, Crary moved to the Icahn School of Medicine at Mount Sinai, establishing a new laboratory and brain bank focused on movement disorders and chronic traumatic encephalopathy. [10] Crary is a frequent invited lecturer at various institutions including the New York Academy of the Sciences, [11] the American Association of Neuropathologists, [12] and others.
Dr. Crary has led efforts to define post-mortem diagnostic criteria for various tauopathies. This includes primary age-related tauopathy, [13] aging-related tau astrogliopathy, [14] chronic traumatic encephalopathy, [15] [16] and progressive supranuclear palsy. [17] He also contributed substantially to understanding the neurological consequences of neuroinfectious diseases such as HIV [18] and SARS-CoV-2. [19]
His genetic studies of on PART [21] and PSP have received considerable attention. [22]
Crary was the first to apply artificial intelligence / machine learning techniques to the histomorphological assessment of neurodegeneration in human brain digital whole slide images of autopsy brain tissues. [23] He has pioneered the use of convolutional neural networks for analyzing whole slide images from dementia patients. Dr. Crary developed an AI/ML algorithm capable of obtaining a pre-mortem tissue diagnosis of Parkinson's disease. [24] Dr. Crary's team was the first to apply convolutional neural networks to assessing tau pathology. [25] [26] The Crary lab showed that deep learning algorithms can predict cognitive function. [27] Using multiple instance learning, Dr. Crary's team developed an approach to measuring brain aging, termed HistoAge, [28] an approach that may help advancing our understanding of age-acceleration. [29]
He is an editor of Acta Neuropathologica [30] and Free Neuropathology. [31]
{{
cite journal}}
: CS1 maint: numeric names: authors list (
link)
{{
cite journal}}
: CS1 maint: numeric names: authors list (
link)
{{
cite journal}}
: CS1 maint: numeric names: authors list (
link)
{{
cite journal}}
: CS1 maint: numeric names: authors list (
link)
{{
cite journal}}
: CS1 maint: numeric names: authors list (
link)
{{
cite journal}}
: CS1 maint: numeric names: authors list (
link)
{{
cite journal}}
: CS1 maint: numeric names: authors list (
link)
{{
cite journal}}
: CS1 maint: numeric names: authors list (
link)